HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Schering Claritin Awaits FDA Certification; Correctol SKUs To Be Discontinued

This article was originally published in The Tan Sheet

Executive Summary

Schering-Plough's first batch of products submitted to FDA for certification under a May 16 consent decree will include the Claritin 10 mg dose

You may also be interested in...

GSK Consent Decree Includes $650 Mil. Bond, Third-Party Inspections

GlaxoSmithKline appears to have negotiated a more favorable consent decree agreement with FDA compared to previous pharmaceutical companies facing similar action

GMP Violations Usually Due To Poor Management Controls – FDA’s Ellsworth

The majority of recent FDA consent decrees have been due to poor oversight by senior company management, not problems inherent in firms' manufacturing controls, according to New Jersey District Director Douglas Ellsworth

Risk-Based GMPs: FDA Priorities Will Reflect Exposure, Compliance Record

FDA's risk-based inspection model will consider a product's breadth of use when assigning inspection priorities

Related Content





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts